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DissolutionAbstract A simple, rapid, and robust stability indicating RP-HPLC method has been developed
and validated to measure thiocolchicoside (TH) and diclofenac potassium (DP) at single wavelength
(258 nm) in order to assess assay and in vitro drug release proﬁle of drug from tablet formulation. A
gradient elution of samples performed on Zorbax SB CN 250 mm · 4.6 mm, 5 lm column with buf-
fered mobile phase consisting solvent A (5 mM sodium dihydrogen phosphate, pH 2.5) and solvent
B (methanol) delivered at ﬂow rate 1.0 mL/min. For dissolution study, the sink condition has been
established from quantitative solubility of TH and DP API in different dissolution medium recom-
mended by USP for immediate release formulation and the optimized dissolution condition was: pH
6.8 deaerated potassium dihydrogen phosphate buffers, paddle rotation speed 50 rpm and vessel
volume 900 mL. Discriminating release of TH and DP achieved more than 96% of labeled amount
over 45 min and drug dissolution was concluded after 60 min. The HPLC method and dissolution
test condition were validated to meet requirement for regulatory ﬁlling and this validation inferred
from speciﬁcity, precision, accuracy, linearity and robustness. In addition ﬁlter suitability, standard
and sample solution stability was demonstrated.All results were acceptable and this conﬁrmed that
the method is suitable for its intended use in routine quality control and assay of drugs.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
Thiocolchicoside (TH) is (s)-N-[3-(BD-glucopyranoxyloxy)-
5,6,7,9-tetrahydro-1,2-dimethoxy-10-(methylthio)9-oxobenzo-
[a]heptalen-7yl]acetamide, sulfur derivative of cochicoside
(Fig. 1a) and possesses non-sedating muscle relaxant action
(Merck Index, 1998; Indian Pharmacopoeia, 2010), while
diclofenac potassium (DP) is 2-[(2,6-dichlorophenyl)amino]
Figure 1 Chemical structure of (a) thiocolchicoside (TH) and (b)
diclofenac potassium (DP).
Validated stability indicating RP-HPLC method for simultaneous determination and in vitro dissolution 119phenyl acetic acid (Fig. 1b) which possesses anti-inﬂammatory
and analgesic properties (Indian Pharmacopoeia, 2010; British
Pharmacopoeia, 2004; United State Pharmacopoeia, 2005).
The combination of TH and DP have synergetic action and
is prescribed for symptomatic relief of low back pain, post
operative pain, and rheumatic arthritis osteoarthritis, muscu-
loskeletal injuries and chronic pain associated with cancer
(Janbroers, 1987).
Literature survey revealed that several analytical methods
have been described for analysis of TH as single component
or in combinations with other drugs, Viz-spectrophotometric
methods (Sutherland et al., 2002; Lu et al., 2006), TLC (El-
Ragehy et al., 2003), HPLC (Ondra et al., 1995; Rosso and
Zuccaro, 1998; Tracqui et al., 1996) and radioimmunoassay
(Sandouk et al., 1995). Similarly literature of DP revealed sev-
eral spectrometric methods (Agatonovic-kustrin et al., 1997;
Botello and Caballero, 1995; Matin et al., 2005; Sparidans
et al., 2008) as well as chromatographic methods (Vora
et al., 2007; Kaphalia et al., 2006; Lee et al., 2000; Klimes
et al., 2001) for determination of DP as single drug or in com-
bination with other drugs.
However, the exhaustive literature survey revealed that
none of the most recognized pharmacopoeias or any journals
includes these drugs in combination for the simultaneous
determination of TH and DP and the information regarding
the stability of the drugs is not available. So it is felt essential
to develop a liquid chromatographic procedure which will
serve a reliable, accurate and stability indicating HPLC
method for the simultaneous estimation and in vitro dissolu-
tion studies of TH and DP in tablet dosage form.
The main purpose of an oral solid pharmaceutical dosage
form is to make available a certain and deﬁned amount of
active substance to human body through the gastrointestinal
system (Morrison and Campbell, 1965). The pharmaceutical
industry and the regulatory agencies focus on the evaluation
of the release kinetics from dosage forms, and this study is
generally performed on ofﬁcial or nonofﬁcial dissolution
devices (Jashnani et al., 1993). The in vitro dissolution pro-
ﬁles obtained from dissolution rate studies have also been
used in an attempt to characterize the in vivo behavior of
drugs with little success (Rowe and Carless, 1981; Anchisi
et al., 1998; Satiropoulus et al., 1981). The signiﬁcance of
stability testing is to provide evidence on how the quality
of a
drug substance or drug product varies with time under the
inﬂuence of a variety of environmental factors such as
temperature, humidity, and light, enables recommendation
of storage conditions, retest periods, and shelf lives to be
established.
The principal aspects of drug products that play an impor-
tant role in shelf life determination of tablet formulation are
assay and dissolution of active drug and degradants generated
during the stability study. The assay of drug product in stabil-
ity test sample needs to be determined using stability indicating
method, as recommended by the International Conference on
Harmonization (ICH) guidelines (ICH, 2000) and USP 29
(United State Pharmacopoeia, 2005).
The main purpose of this investigation is to develop and
validate simple, precise, sensitive and accurate stability indicat-
ing reversed phase high-performance liquid chromatographic
methods for assay and in vitro dissolution studies.2. Experimental
2.1. Chemicals and reagents
All reagents and solvent were of analytical and HPLC grade
and included hydrochloric acid, monobasic sodium phos-
phate, monobasic potassium phosphate, sodium acetate tri-
hydrate, orthophosphoric acid and methanol were
purchased from Merck Ltd., Mumbai, India. Wockhardt
Ltd., Aurangabad, India, kindly supplies TH and DP API,
tablet and placebo of tablet. High purity deionized water
was obtained from Millipore, Milli-Q (Bedford, MA, USA)
puriﬁcation system. The 0.45-lm nylon ﬁlters were pur-
chased from Advanced Micro Devices Pvt. Ltd., Chandi-
garh, India.
2.2. Instrumentations
HPLC system (Waters Milford, USA) equipped with in built
auto-sampler and quaternary gradient pump with an on-line
degasser was used. The column compartment having tempera-
ture control, photodiode array (PDA) detector (2996) and dual
wavelength detector (2487) was employed throughout the anal-
ysis for detection. Chromatographic data was acquired using
Empower software-2. All dissolution experiments were carried
out using a dissolution instrument Electro lab TDT-08L (Elec-
trolab, India) attached to auto-sampler.
2.3. Chromatographic condition
Zorbax SB CN 250 mm · 4.6 mm, 5 lm (Agilent technology,
USA) column was used as stationary phase maintained at
ambient temperature. Gradient elution with the mobile phase
involved a variable composition of solvent A (5 mM sodium
dihydrogen phosphate, pH 2.5) and solvent B (methanol).
The mobile phase was pumped through the column with ﬂow
Table 1 Mobile phase program for gradient elution.
Time (min) Flow (mL min1) Solvent A (%) Solvent B (%)
0 1.0 60 40
1 1.0 60 40
10 1.0 20 80
11 1.0 60 40
15 1.0 60 40
120 S.D. Jadhav et al.rate of 1 mL min1 (Table 1). Injection volume 20 lL was used
in all experiments.
The optimum wavelength selected was 258 nm, which rep-
resents the wavelength of maximum response for both TH
and DP. The stressed samples were analyzed using a PDA
detector covering the range of 200–400 nm.
2.4. Preparation of standard solution and calibration graph
2.4.1. For assay method
Mixed Standard stock solution of 80 lg mL1 of TH and
50 lg mL1 of DP was prepared by dissolving about 80 mg
of TH reference standard and about 50 mg DP reference
standard in 30 mL of diluent which was a mixture of
water:methanol (50:50, v/v) in 100 mL volumetric ﬂask and
stirred in an ultrasonic bath for 10 min. The volume was com-
pleted with the same diluent. Further diluted 5 mL of mixed
standard stock to 50 mL with the same diluent.
To study the linearity range of each component, the serial
dilutions of mixed standard stock were made in the range of
40.48–121.43 lg mL1 of TH and 24.91–74.72 lg mL1 of
DP (i.e. 50–150% of test concentration). A graph was plotted
as concentration of drugs versus peak area response. It was
found to be linear for both the analytes. The system suitability
test was performed from ﬁve replicate injections of mixed stan-
dard solution.
2.4.2. For in vitro dissolution studies
Standard stock of TH (8.8 lg mL1) was prepared by dissolv-
ing about 88 mg of reference standard of TH in 100 mL of dil-
uent which was respective dissolution media, this 5 mL
solution to 50 mL was diluted with same diluent. Standard
solution of DP (55 lg mL1) was prepared by dissolving about
55 mg reference standard of DP into 100 mL of same diluent.Figure 2 A typical chromatogram of a tablet sample solution contai
potassium.The mixed standard was prepared by mixing 5 mL of standard
stock of TH and 5 mL of DP standard stock solution.
To study linearity of each component, the serial dilution of
TH and DP stocks were made in the range of 0.4–13.19 lg
mL1 of TH and 2.7–82.50 lg mL1 of DP (i.e. 1–150% test
concentration). A graph was plotted as concentration of drugs
versus peak area response. It was found to be linear for both
the analytes. The system suitability test was performed from
ﬁve replicate injections of mixed standard solution.
2.5. Preparation of sample solution
2.5.1. For assay method
Twenty tablets each containing 8 mg of TH and 50 mg DP
were weighed, averaged and ﬁnely powdered. A portion of
powder equivalent to the weight of one tablet was accurately
weighed into 100 mL A-grade volumetric ﬂasks and 70 mL dil-
uent was added. The volumetric ﬂasks were sonicated for
20 min to effect complete dissolution of the TH and DP in
the solutions, and then made up to volume with diluent. The
solution was ﬁltered through 0.45 lm nylon ﬁlter.
TH sample (80 lg mL1) – aliquot portion of ﬁltrate use as
such.
DP sample (50 lg mL1) – further dilute aliquot portion of
the ﬁltrate to 50 mL with diluent.
Twenty microliters of test solution was injected and chro-
matogram was recorded for the same and amount of drug
calculated.
2.5.2. For in vitro dissolution studies
A calibrated dissolution tester was used with paddle (USP-II)
at 50 rpm and bath temperature maintained at 37 ± 5 C.
Nine hundred milliliters of freshly prepared and degassed pH
6.8 phosphate buffers was used as dissolution medium. Six tab-
lets were evaluated. Dissolution samples were collected at 5,
10, 15, 30, 45, 60 min. At each time point, a 10 mL sample
was removed from each vessel using an auto-sampler and ﬁl-
tered through a 0.45 lm nylon ﬁlter into labeled glass tubes
and analyzed by HPLC.
2.6. Forced degradation sample solution for speciﬁcity
Multiple stressed samples were prepared as indicated below.
They were chromatographed along with a non-stressed as con-
trol sample.ning 80 lg mL1 of thiocolchicoside and 50 lg mL1 of diclofenac
Table 2 Summary of stationary phases used to optimize the method.
Stationary phase Dimension Observation
Rt (min) Capacity factor (K
0) Separation factor (a)
TH DP TH DP
Hypresil C18 150 · 4.6 mm, 5 lm 1.2 a 0.07 – –
250 · 4.6 mm, 5 lm 2.1 a 0.14 – –
Kromasil C18 250 · 4.6 mm, 5 lm 2.4 a 0.30 – –
Hypresil C8 250 · 4.6 mm, 5 lm 2.5 23.8 0.35 11.86 33.8
Hypresil phenyl 250 · 4.6 mm, 5 lm 2.6 14.7 0.41 6.95 17.1
Zorbax SB CN 250 · 4.6 mm, 5 lm 5.8 11.0 2.14 4.95 2.3
a Peak not eluted up to 60 min.
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Figure 3 Drug release of TH and DP.
Table 4 System suitability parameters.
Parameters TH DP
Assay Dissolution Assay Dissolution
Theoretical plates 69,992 12,169 24,219 68,601
USP tailing (Tf) 1.31 1.05 1.18 1.06
Resolution – – 11.87 11.23
Capacity factor 2.14 2.34 4.92 5.04
% RSD 0.12 1.84 0.16 1.36
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Solutions containing 80 lL of TH and 50 lL of DP were trea-
ted with different conc. of HCl and NaOH which was 0.1 N,
0.5 N and 1 N for 30 min at 80 C. The solutions were neutral-
ized as needed.
2.6.2. Oxidative condition: hydrogen peroxide-induced
degradation
Sample was treated with 5 mL of 5% and 10% w/v H2O2 in
dark under the condition 80 C for 30 min.
2.6.3. Thermal degradation
To investigate the stability of the drugs under thermal stress
conditions, sample was spread in a thin layer on a petri plate
and subjected to the conditions indicated at 60 C for 12 h.
2.6.4. Photolytic degradation
Photolytic studies were performed after exposition of sample
in solid state and diluted in puriﬁed water, subjected in a photo
stability chamber up to 22 h.
Similarly the placebo of tablet was treated as same like
above in each condition separately and tested. All these
stressed samples and placebos were periodically analyzed by
HPLC for the appearance of degradant impurity, calculated
against main drug component.
3. Result and discussion
3.1. Optimization of chromatographic condition
It was clear from the molecular structure of TH and DP
(Fig. 1) that TH is weak base of pKa value 10 and very polar
in nature while, DP is weak acid of pKa value 4 and less polar
than TH.
The main aim of this study is to analyze the polar drugs
with sufﬁcient resolution in reasonable analysis time. ToTable 3 Quantitative solubility and sink condition veriﬁcation of d
Properties pH 4.5 Acetate buﬀer dis
TH D
mg mL1 dissolved 11.44 0.
mg 900 mL1 dissolved 10,296 2.
Sink condition requirement (mg 900 mL1) 24 15
Conclusion Satisfy Fobtain a good chromatographic condition, different stationary
phases were tested considering:
(a) The feature of stationary phase (RP-C8 and RP-C18,
Phenyl and Cyano column).
(b) The particle size of the column (3 lm and 5 lm).
Considering that TH and DP are having different pKa, we
tested following mobile phases with gradient elution:rugs.
solution media pH 6.8 Phosphate buﬀer dissolution media
P TH DP
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Figure 4 Typical HPLC chromatogram of 1 N HCl stressed sample of TH (a) and DP (b).
122 S.D. Jadhav et al.(a) KH2PO4, K2HPO4, 0.3 mL L
1 orthophosporic acid as
a buffer (pH 2.5, 3.5 and 6.5) in combination with
methanol.
(b) NaH2PO4 Na2HPO4 and 0.3 mL L
1 orthophosphoric
acid as a buffer (pH 2.5, 3.5 and 6.5) in combination
with methanol.
(c) Water:methanol:acetonitrile:triethylamine (75:15:10:01)
and 1-pentane sulfonic acid of pH 2.5 and 3.5.3.1.1. Selection of stationary phase
As both drugs were polar in nature they can readily ionize.
Hence we started the development activity with different
stationary phases starting from non-polar to polar, i.e. C18,C8, Phenyl, and Cyano of various manufacturers using differ-
ent mobile phases. Columns with C8 and C18 stationary phases
were tried for better peak shape and resolution, but TH was
eluting at about void volume due to the highly polar nature
indicating that it is not retaining on the column surface but
eluting with mobile phase. Hence to retain the peaks the polar
stationary phase needs to be used. The poor resolution
between TH and DP and distorted peak shape on phenyl col-
umn implies that this column is also not suitable for this appli-
cation. Hence column with Cyano stationary phase was chosen
to improve the peak shape and resolution among the peaks.
The peak shape and system suit parameters among all compo-
nents were improved with Zorbax SB CN (250 mm · 4.6 mm,
5 lm) column (Fig. 2 and Table 2). But the stationary phase
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Figure 5 Typical HPLC chromatogram of 1 N NaOH stressed sample of TH (a) and DP (b).
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phy. Mobile phase pH and organic modiﬁers also play very
important role which leads to the best chromatographic
condition.
3.1.2. Selection of mobile phase
Highly polar substances, especially those which take ionized
form in water, have peak tailing and bad peak symmetry
when separated by applying the RP-HPLC method, which
affects resolution, sensitivity and reproducibility. Hydrogen
bonding and ion exchange interaction can occur betweenthe chromatographic support and the basic compounds. It
can be prevented by addition of modiﬁer to the mobile phase
such as acid, base and ion pairing agents. More accepted
approach is to adjusted pH value of the mobile phase (Swa-
desh, 1997).
The elution of TH and DP was done using ion pair agent 1-
pentane sulfonic acid in mobile phase containing water and
water:acetonitrile:triethylamine (75:15:10 v/v/v) but elution
of TH occurred at void volume, while DP does not elute up
to 60 min on different stationary phases given in Table 2.
The buffer KH2PO4, K2HPO4, Na2HPO4, NaH2PO4 and
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Figure 6 Typical HPLC chromatogram of 10% H2O2 stressed sample of TH (a) and DP (b).
124 S.D. Jadhav et al.sodium acetate were tested. The good performance and better
separation was achieved in NaH2PO4 buffer and methanol
using Cyano stationary phase (Fig. 2). We optimized the elu-
tion by setting gradient program at ﬂow rate 1.0 mL min1
(Table 1).
3.1.3. Inﬂuence of pH and organic modiﬁer
The molecular structure of both components implies that TH
is having amide group and DP is having carboxylic acid func-
tional group, which makes separation pH sensitive. For themethod to be robust, pH of mobile phase must not be at
pKa of compounds. The basic pH deteriorates the silica in
HPLC column. We tried different mobile phase buffers pH
ranging from 2.5 to 5 and monitored the resolution and perfor-
mance of column. The best separation was achieved with pH
2.5. DP was not eluted on polar (Cyano) stationary phase as
it retains due to polar likes polar theory. To elute within our
satisfactory run time, organic modiﬁer composition needs to
be increased. The satisfactory elutions were observed at gradi-
ent program mentioned in Table 1.
Figure 7 Degradation trends of TH and DP in acidic (a), basic
(b) and peroxide (c) stressed condition.
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3.2.1. Solubility determination and sink condition veriﬁcation
Drug solubility and solution state stability need to be deter-
mined before selecting the dissolution medium. The dissolution
characteristics of an oral formulation should be evaluated in
the physiologic pH range of 1.2–6.8 (1.2–7.5 for modiﬁed-
release formulations). USP <711>. Solubility data were used
as the basis for the selection of a dissolution medium for TH
and DP. Drugs solubility was determined at 37 C in 0.1 N
HCl, pH 4.5 acetate buffer and pH 6.8 phosphate buffers.
DP is practically insoluble in 0.1 N HCl. The quantitative
solubility of drugs was determined in pH 4.5 acetate buffer
and pH 6.8 phosphate buffer. Based on solubility results for
TH and DP in each dissolution medium tested (Table 3) and
considering a test volume of 900 mL per vessel, sink conditions
were veriﬁed. The term sink conditions is deﬁned as the volume
of medium at least greater than three times of that required to
form a saturated solution of drug substance (United State
Pharmacopoeia, xxxx; Tracqui et al., 1996). A pH 6.8 phos-
phate buffer was used as dissolution media for TH and DP
tablet (Table 3).
3.2.2. Development of the dissolution test condition
From pre-selected, pH 6.8 phosphate buffer media, dissolution
testing was performed on tablet (n= 6) in compliance with
USP <711> using paddle (USP-II). A paddle speed of
50 rpm was selected to minimize coning. The media volume
used 900 mL. The medium which was vacuumed and degassed
under house vacuum was maintained at 37 ± 0.5 C. The 1-L
glass dissolution vessels were covered to minimize evaporation.
Samples were drawn at 5, 10, 20, 30, 45, 60 min. The tablet was
immediate releasing, the earlier time points provided more dis-
criminating ability (Fig. 3). Sampling was performed using
auto sampler of 10 mL aliquots. This solution was immediately
ﬁltered using a syringe of 0.45 lm nylon ﬁlters. The ﬁrst 2–
3 mL of sample was discarded prior to collecting the sample
for analysis.
3.3. Method validation
The optimized RP-HPLC method for assay method and
in vitro dissolution studies validated according to ICH guide-
lines (ICH, 2000, 2005) with respect to speciﬁcity, accuracy,
precision (repeatability and intermediate precision), linearity,
range and robustness. System suitability features were also
assessed.
3.3.1. System suitability test
The system suitability test performed according to USP 29
(United State Pharmacopoeia, xxxx) and BP 2007 (British
Pharmacopoeia, 2004) indications. The observed RSD values
at 1% level of analyte concentration were well within the usu-
ally accepted values (62%). Theoretical plates, USP tailing
factor (Tf) and USP resolution (Rs) between TH and DP were
determined for both assay and dissolution. The results are all
within acceptable limits summarized in Table 4.
3.3.2. Speciﬁcity
The speciﬁcity of Assay HPLC method carried out by the peak
purity indices for the analytes in stressed solutions were deter-mined with PDA detector (Young and Gorenstein, 1994)
under optimized chromatographic conditions found to be bet-
ter (purity angle < purity threshold) indicating that no addi-
tional peaks were co-eluting with the analytes and evidencing
the ability of the method to assess unequivocally the analyte
of interest in the presence of potential interference. Baseline
resolution was achieved for all investigated compounds. The
FDA guidelines indicated that well separated peaks, with res-
olution, Rs > 2 between the peak of interest and the closest
Table 5 Results of recovery analysis of TH and DP.
Compound Wt. spiked (mg) Wt. recovered (mg) Recovery (%) RSD (%)
AM DM AM DM AM DM AM DM
TH 39.4 4.40 39.5 4.34 100.25 98.64 0.29 0.97
78.9 8.80 79.1 8.75 100.25 99.43 0.24 0.34
118.3 13.19 118.5 13.09 100.17 99.24 0.04 0.50
DP 25.15 27.67 25.10 27.79 99.80 100.43 1.31 0.95
50.32 55.39 50.00 54.97 99.36 99.24 0.31 0.76
75.49 83.10 74.98 84.33 99.32 101.48 0.99 0.30
RSD: Relative standard deviation; Wt: weight, AM: assay method; DM: dissolution method.
Table 6 Linearity study parameters.
Parameter Assay Dissolution
TH DP TH DP
Linearity
range (lg/mL)
40.48–121.43 24.91–74.72 0.44–13.19 2.75–82.50
Slope 45,089 24,272 44,933 26,144
Intercept 313.860 141.555 1066.831 2354.605
Correlation
coeﬃcient (r)
0.999 1.000 1.000 0.998
126 S.D. Jadhav et al.eluting peak, are reliable for the quantiﬁcation (FDA, 1994).
All stressed samples peak of TH and DP meet this speciﬁca-
tion. Major degradation impurity formed by both drug in
hydrolytic stressed condition at 1 N HCl and NaOH and in
oxidative condition at 10% H2O2, visibly conﬁrmed in Figs.
4–6.
Dissolution method speciﬁcity was examined by analyzing a
solution of a placebo containing the excipients mixture for the
TH and DP tablet dissolved in the dissolution medium.
Absence of interference was demonstrated.
3.3.2.1. Degradation kinetics of drugs in stressed condition.
Sample solutions were treated with HCl, NaOH of different
normality and H2O2 at different concentration. The chromato-
gram obtained revealed that the peak area for TH was
degraded in all stressed conditions while DP peak area
degraded only in acidic condition. The percentage degradation
of each compound was calculated with respect to the con-
trolled sample. The plot of respective component % degrada-
tion against concentration of HCl, NaOH and percentage of
H2O2 indicated an apparent ﬁrst order degradation of TH inTable 7 Factors of robustness study.
Low
For HPLC method
pH 2.3
Flow rate (mL/min) 0.8
Temperature (C) 20
For dissolution test
Paddle Teﬂon coated (TC)
Sampling device A
Degassing procedure Overnight house vacuum (HV)all conditions and DP only in HCl conditions (Fig. 7). In ther-
mal and photolytic conditions, the solution was stable.
3.3.3. Accuracy
Accuracy of the assay method as well as dissolution method
was calculated by recovery studies at three concentrations of
50%, 100%, and 150% levels by standard addition method
(Table 5). The mean percentage recoveries obtained for TH
were 100.25% for assay and 99.43% for dissolution, while
99.81%, 99.29% for DP assay and dissolution, respectively.
3.3.4. Linearity and range
The linearity of the HPLC detector response for TH and DF
was determined for their assay method and dissolution method
by analyzing series of different concentrations of each
compound.
The plots of area under the curve (AUC) of the peak
responses of the analytes against their corresponding concen-
trations, they exhibit linear responses with r> 0.999 for both
methods. All the validation parameter such as a correlation
coefﬁcient, concentration ranges are summarized in Table 6.3.3.5. Robustness
In order to demonstrate the robustness of the assay method,
system suitability parameters were evaluated in the study as
shown in Table 7 and include pH, ﬂow rate, column tempera-
ture. The parameters and criteria used to deﬁne robustness
were retention time (>4.5 and 66.5 min for TH and >10.8
and 612.8 min for DP), peak symmetry (62.0) and efﬁciency
(>2000).
The most important factors that affect peak asymmetry are
% of organic, ﬂow rate and temperature. The method, how-
ever, is robust with respect to peak asymmetry; this valueNominal High
2.5 2.7
1.0 1.2
25 30
Teﬂon coated (TC) Solid teﬂon (ST)
B B
15 min degas (15 min) Overnight open and stirring (OS)
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Method suitability, therefore, will not be adversely affected
with respect to peak asymmetry.
Flow rate is the parameter that signiﬁcantly affects peak efﬁ-
ciency. Themethod, however, is robust with respect to peak efﬁ-
ciency; this value was consistent >4000 across all value of these
parameters. Method suitability, therefore, will not be adversely
affected with respect to peak efﬁciency. The mobile pH, in the
study 1.5 and 3.5 has negligible affect on suitability criteria.
To evaluate robustness of the dissolution test, the variable
selected mention in Table 7 includes paddle type, sampling
device and degassing procedure. The variables were chosen
as they were deemed the most signiﬁcant factors that can
potentially affect the rate of dissolution. The degassing proce-
dure parameter involves three conditions. The media was
either left spinning in an open ﬂask overnight, left vacuum
degassing overnight or vacuum degassing for 15 min as per
the method. The ﬁrst two options chosen to maximize and
minimize, respectively, the amount of dissolved oxygen in the
media. The all variable not signiﬁcantly affect on % drug
release.
4. Conclusion
A stability indicating RP-HPLC method has been reported for
simultaneous estimation and in vitro dissolution studies of
thiocolchicoside (TH) and diclofenac potassium (DP) in tablet
dosage form. The proposed method gives good resolution of
TH, DP and degradant form in degradation study. The degra-
dation kinetics studies of drugs was also carried out and TH
degrade with ﬁrst order in acid, base and peroxide stressed
condition, while ﬁrst order degradation of DP only in acidic
condition.
The proposed method successfully applied for studying
in vitro dissolution of TH and DP from tablet dosage form.
The discriminating dissolution medium was selected by study-
ing quantitative solubility both drugs and conﬁrmation of sink
condition in each media as per USP dissolution guidelines. The
validation of proposed method was done as per ICH guidelines
and proved that method to be simple, precise, reliable and
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